You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 27, 2024

Claims for Patent: 10,828,310

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,828,310

Title:	Reducing the risk of cardiovascular events
Abstract:	Combination therapy with rivaroxaban and aspirin successfully reduces the risk of cardiovascular events in patients who have coronary artery disease and/or peripheral artery disease.
Inventor(s):	Bruns; Nancy Cook (Kassel, DE), Misselwitz; Frank (Heidelberg-Neuenheim, DE), Eikelboom; John William Andrew (Hamilton, CA), Connolly; Stuart J. (Hamilton, CA), Yusuf; Salim (Hamilton, CA)
Assignee:	BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)
Application Number:	16/264,032
Patent Claims:	1. A method of reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral artery disease, comprising administering to the human patient rivaroxaban and aspirin in amounts that are clinically proven effective in reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral arterial disease, wherein rivaroxaban is administered in an amount of 2.5 mg twice daily and aspirin is administered in an amount of 75-100 mg daily. 2. The method of claim 1, wherein aspirin is administered in an amount of 100 mg daily. 3. The method of claim 1, wherein aspirin is administered in an amount of 81 mg daily. 4. The method of claim 1, wherein aspirin is administered in an amount of 75 mg daily. 5. A method of reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral artery disease, the method comprising administering to the human patient rivaroxaban and aspirin in amounts that are clinically proven effective in reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral arterial disease, wherein the method comprises once daily administration of a first product comprising rivaroxaban and aspirin and a second product comprising rivaroxaban, and further wherein the first product comprises 2.5 mg rivaroxaban and 75-100 mg aspirin and the second product comprises 2.5 mg rivaroxaban. 6. The method of claim 5, wherein the first product comprises 75 mg aspirin. 7. The method of claim 5, wherein the first product comprises 81 mg aspirin. 8. The method of claim 5, wherein the first product comprises 100 mg aspirin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.